Antiemetic effect of nonabine in cancer chemotherapy

Por Harvey, Vernon J, Slevin, Maurice L, Wrigley, Peter F M
Publicado em 1983

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study

Por North, Richard T, Harvey, Vernon J, Cox, Levonne C, Ryan, Stuart N
Publicado no Clinicoecon Outcomes Res (2015)

Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?

Por Tin Tin, Sandar, Elwood, J. Mark, Lawrenson, Ross, Campbell, Ian, Harvey, Vernon, Seneviratne, Sanjeewa
Publicado no PLoS One (2016)

Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology

Por Seneviratne, Sanjeewa, Lawrenson, Ross, Harvey, Vernon, Ramsaroop, Reena, Elwood, Mark, Scott, Nina, Sarfati, Diana, Campbell, Ian
Publicado no BMC Cancer (2016)

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination c...

Por Lee, Chee Khoon, Gebski, Val J, Coates, Alan S, Veillard, Anne-Sophie, Harvey, Vernon, Tattersall, Martin HN, Byrne, Michael J, Brigham, Brian, Forbes, John, Simes, R John
Publicado em 2013

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Por Phillips, Kelly Anne, Ribi, Karin, Sun, Zhuoxin, Stephens, Alisa, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Bernhard, Jürg
Publicado em 2010

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Por Phillips, Kelly-Anne, Aldridge, Julie, Ribi, Karin, Sun, Zhuoxin, Thompson, Alastair, Harvey, Vernon, Thürlimann, Beat, Cardoso, Fatima, Pagani, Olivia, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Bernhard, Jürg
Publicado em 2010

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Por Leyland-Jones, Brian, Gray, Kathryn P., Abramovitz, Mark, Bouzyk, Mark, Young, Brandon, Long, Bradley, Kammler, Roswitha, Dell’Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Harvey, Vernon, Neven, Patrick, Arnould, Laurent, Maibach, Rudolf, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Viale, Giuseppe, Rae, James M., Regan, Meredith M.
Publicado no Breast Cancer Res Treat (2015)

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

Por Leyland-Jones, Brian, Gray, Kathryn P., Abramovitz, Mark, Bouzyk, Mark, Young, Brandon, Long, Bradley, Kammler, Roswitha, Dell'Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Harvey, Vernon J., Neven, Patrick, Treilleux, Isabelle, Rasmussen, Birgitte Bruun, Maibach, Rudolf, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Pagani, Olivia, Viale, Giuseppe, Rae, James M., Regan, Meredith M.
Publicado no Breast Cancer Res Treat (2015)